Impax launches authorized generic of Zomig, as Mylan debuts copy of Tricor in USA

20 May 2013

US drugmaker Impax Laboratories (Nasdaq: IPXL) says that its generics division, Global Pharmaceuticals, commenced shipment of an authorized generic version of Zomig (zolmitriptan) tablets and orally disintegrating tablets, 2.5mg and 5mg, in the USA, as part of a distribution, license, development and supply agreement with Anglo-Swedish drug major AstraZeneca (LSE: AZN).

Zomig is indicated for the treatment of migraine headaches in adults. According to IMS Health data quoted by Impax, US sales of Zomig tablets and orally disintegrating tablets were around $196 million in the 12 months ended April 2013.

Mylan starts shipping generic of AbbVie’s Tricor

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK